Insulin resistance: site of the primary defect or how the current and the emerging therapies work.
about
Renal dysfunction, metabolic syndrome and cardiovascular disease mortality.Nocturnal hypoglycemia: answering the challenge with long-acting insulin analogs.Metabolic syndrome in hemodialysis patients as a risk factor for new-onset diabetes mellitus after renal transplant: a prospective observational study.Obesity and central fat pattern among Greenland Inuit and a general population of Denmark (Inter99): Relationship to metabolic risk factors
P2860
Insulin resistance: site of the primary defect or how the current and the emerging therapies work.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Insulin resistance: site of th ...... d the emerging therapies work.
@ast
Insulin resistance: site of th ...... d the emerging therapies work.
@en
type
label
Insulin resistance: site of th ...... d the emerging therapies work.
@ast
Insulin resistance: site of th ...... d the emerging therapies work.
@en
prefLabel
Insulin resistance: site of th ...... d the emerging therapies work.
@ast
Insulin resistance: site of th ...... d the emerging therapies work.
@en
P2860
P1476
Insulin resistance: site of th ...... d the emerging therapies work.
@en
P2093
J W Kolaczynski
P2860
P304
P356
10.1515/JBCPP.1998.9.2-4.281
P577
1998-01-01T00:00:00Z